Tetanus Severity Score for Prediction of Mortality in Manifest Tetanus
ConditionTetanus, Manifest
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAin Shams University
About this trial
Three scoring systems will be applied to patients suffering from manifest tetanus and will be related to mortality.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adults (age 18 years old or more).
Any sex (male or female), regardless of gender identity.
Sustained spasm of the facial muscles in which person appears grinning.
Painful muscular contractions
Disqualifiers
Age < 18 years.
Absent criteria of manifest tetanus, as per the WHO criteria (https://www.who.int/news-room/fact-sheets/detail/tetanus).
Incomplete medical record with missing data required to calculate the Tetanus Severity Score, Philips Score, or Dakar score.
Incomplete medical record with missing data regarding the primary outcome measure (survival to hospital discharge or in-hospital mortality).
Trial population
Adults of both sexes with manifest tetanus.
Trial design
Design model
Cohort
Time perspective
Retrospective
Treatments tested in this trial
Tetanus Severity Score (TSS)
Diagnostic testThe Tetanus Severity Score (TSS) is calculated for each patient by the investigator using the required data as documented in the medical records at admission
Philips Score
Diagnostic testThe Philips Score is calculated for each patient by the investigator using the required data as documented in the medical records at admission
Dakar Score
Diagnostic testThe Dakar Score is calculated for each patient by the investigator using the required data as documented in the medical records at admission
Treatment groups
115 Participants
are divided into 2 treatment groupsGroup A: Non-survivors3 interventions
Group B: Survivors3 interventions
Trial outcomes
Primary outcomes
1
Death from any cause.
Occurrence of death from any cause, assessed from the date of onset of symptoms up to 90 days.
Time frame
From the date of onset of symptoms until the date of death or date of discharge from the hospital, whichever comes first, assessed up to 90 days.Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov